Clinical Trial Update: Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sequential bendamustine debulking followed by obinutuzumab, acalabrutinib, and venetoclax in relapsed/refractory chronic lymphocytic le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• CALQUENCE (ACALABRUTINIB)
• Gazyva (Obinutuzumab)
• Venclexta (venetoclax)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphoid Leukemia | Phase 2 | Status: COMPLETED